Compugen Ltd. (NASDAQ:CGEN) Short Interest Update

Compugen Ltd. (NASDAQ:CGEN) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,270,000 shares, a decline of 18.1% from the October 15th total of 1,550,000 shares. Based on an average daily trading volume, of 225,400 shares, the short-interest ratio is presently 5.6 days.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Atom Investors LP raised its holdings in Compugen by 27.5% in the third quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 32,701 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Compugen by 82.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 124,190 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock worth $35,000 after buying an additional 8,350 shares during the period. Joel Isaacson & Co. LLC lifted its holdings in Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 16,253 shares during the period. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Stock Down 5.4 %

Shares of Compugen stock opened at $1.41 on Friday. The business has a fifty day simple moving average of $1.75 and a 200 day simple moving average of $1.87. The stock has a market cap of $125.82 million, a PE ratio of 70.50 and a beta of 2.64. Compugen has a 12 month low of $0.61 and a 12 month high of $3.03.

Compugen (NASDAQ:CGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.20). The company had revenue of $17.13 million for the quarter, compared to analyst estimates of $17.67 million. Compugen had a return on equity of 2.62% and a net margin of 2.67%. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. Analysts expect that Compugen will post 0.07 EPS for the current fiscal year.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.